94 - Oral Semaglutide vs Placebo in Patients With Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5
Abstract
Patients with type 2 diabetes (T2D) and renal impairment have limited glucose-lowering treatment options. Oral semaglutide 14 mg once daily (n=163) was compared with placebo (n=161) in a 26-week, randomized, phase 3a trial (NCT02827708) in patients with T2D and moderate renal impairment (estimated glomerular filtration rate [eGFR] 30-59 mL/min/1.73 m2), receiving 1-2 glucose-lowering agents (could include basal...
Paper Details
Title
94 - Oral Semaglutide vs Placebo in Patients With Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5
Published Date
Oct 1, 2019
Journal
Volume
43
Issue
7
Pages
S35 - S36
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History